Risk of Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Treated with Conventional Synthetic, Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drugs: Observational Data from the German RABBIT Register

This study by Meissner, et al. estimated the effects of JAKi, TNFi, bDMARDs and csDMARDs on the risk of MACE in RA patients. The authors found no significant difference in MACE risk by treatment group, even among patients at increased CV risk.

This cohort study analysed episodes of RA treatments initiated between January 2017 and April 2022 in the RABBIT register. MACE incidence rates and HRs were calculated for the overall patient cohort and for the increased CV risk subgroup.